ITMCTR2000003622尚未招募4 期
Yiqi Yangyin Jiedu decoction combined with chemotherapy in the treatment of advanced lung adenocarcinoma with EGFR sensitive mutation after TKI resistance: a randomized controlled double-blind study
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 74（—）
- 性别
- All
入选标准
- •1. Patients with stage IIIB or IV lung adenocarcinoma without chemotherapy confirmed by pathology or cytology carried EGFR gene mutations, including exon 19 deletion mutation (19del) and exon 21 point mutation (21l858r).
- •2. The patients who had been treated with EGFR-TKI for more than 3 months showed a rapid increase in tumor load and symptom score <= 2;
- •3. No new gene mutation was detected after drug resistance, and the patients who were going to be treated with platinum containing dual drug chemotherapy as the second-line treatment;
- •4. Patients with deficiency of both qi and Yin according to TCM syndrome differentiation;
- •5. Patients aged 18-74 years, regardless of gender;
- •6. Patients with ECoG score of 1-2 and expected survival time >= 3 months;
- •7. For patients without major organ dysfunction, blood routine test, liver, kidney and heart function meet the following requirements: hemoglobin >= 120g / L, absolute neutrophil count (ANC) >= 1.5 * 10^9 / L, platelet >= 80 * 10^9 / L, bilirubin <= 1.5uln, alkaline phosphatase (AP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 2.5 * ULN. INR <= 1.5, creatinine <= 1.5uln.
排除标准
- •1. Patients with other tumor history within 5 years;
- •2. Those who carry T790M mutation and plan to use EGFR-TKI third generation drugs or meet the second-line targeted therapy and immunotherapy;
- •3. Patients who have a history of radiotherapy and are ready to receive radiotherapy in recent 2 months
- •4. Symptomatic brain metastases;
- •5. Those who have been or are participating in other clinical studies;
- •6. History of cardiovascular disease: congestive heart failure > NYHA class II. Patients with unstable angina (angina symptoms resting) or new onset angina (starting in the last 3 months) or myocardial infarction occurred in the past 6 months. Active infection, > grade 2 adverse events (CTC AE. 5.0);
- •7. Pregnant or lactating patients;
- •8. Patients with uncontrollable mental history.
研究者
相似试验
尚未招募
1 期
Shishi Yiqi Bushen Tongluo decoction combined with manipulation in the management of wrist stiffness after distal radius fractureITMCTR2000002916Huangpu Branch, Shanghai Ninth People's Hospital
招募中
1 期
The Clinical study of Yiqi Jiedu compound combined with Pembrolizumab in the treatment of non-small cell lung cancer patients with chemotherapy resistancenon-small lung cancer cell, NSCLCITMCTR2000003721ongHua Hospital, Shanghai University of Traditional Chinese Medicine
招募中
Unknown
Yangxue Qingluo Mingmu Decoction for the Treatment of High Myopia Caused by Deficiency Fire and Collateral Damage Clinical study of macular hemorrhageMacular hemorrhage in high myopiaITMCTR2023000012Eye Hospital of China Academy of Chinese Medical Sciences
招募中
1 期
Yishengukang Decoction for strengthening the healthy, detoxifying and removing blood stasis in the treatment of cancerous somatic pain:A Multi-Center Randomized Controlled TrialCarcinomatous somatic painITMCTR2100004499Qinglin Zhang
招募中
1 期
A clinical study of Yiqi Huayu Jiedu decoction reducing the risk of postoperative gastric cancer recurrence and metastasis: Study protocol for a randomized controlled trailGastric CancerITMCTR2000003294Jiangsu Province Hospital of Chinese Medicine